By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ADC Therapeutics 

Rue Saint-Pierre 2,

  Lausanne  1003  Switzerland
Phone: 1-212-616-4000 Fax: n/a



Company News
ADC Therapeutics Presents First Clinical Data From Its Novel Antibody-Drug Conjugate ADCT-402 At The International Conference On Malignant Lymphoma 6/19/2017 5:23:31 AM
ADC Therapeutics Presents Interim Data From The First Clinical Study Of Its Novel Antibody-Drug Conjugate ADCT-301 At The 14-ICML 6/16/2017 10:20:43 AM
ADC Therapeutics Receives Orphan Drug Designation For ADCT-402 For The Treatment Of Diffuse Large B-Cell Lymphoma And Mantle Cell Lymphoma 6/13/2017 1:22:49 PM
ADC Therapeutics Doses First Patient In A Phase I Clinical Trial Of ADCT-502 In Patients With Advanced Solid Tumors With HER2 Expression 5/19/2017 11:12:54 AM
Synaffix Enters Into A Commercial License Agreement With ADC Therapeutics 10/20/2016 10:20:11 AM
With Ties to the Bay Area, ADC Therapeutics Pulls in $105 Million 10/18/2016 5:44:33 AM
ADC Therapeutics Doses First Patient In Phase I Trial Of ADCT-402 In CD-19 Positive B-cell Non-Hodgkin Lymphomas 3/11/2016 9:32:06 AM
ADC Therapeutics Doses First Patient In Phase I Trial Of ADCT-301 Trial In Acute Myeloid Leukemia 2/9/2016 9:41:26 AM
ADC Therapeutics Announces Positive Pre-clinical Results For Two Of Its Novel Adcs At The American Society of Hematology Conference 12/7/2015 1:49:40 PM
ADC Therapeutics Receives FDA Clearance To Begin Clinical Studies For Its Second Novel Antibody Drug Conjugate ADCT-402 Against Lymphomas And Leukemia 12/4/2015 9:55:02 AM